GSK technologies
GSK has the broadest vaccine platform technology portfolio in the industry. This enables us to select the most promising technology approach (or combinations of different platform technologies) to develop new vaccines not previously thought possible.
The success of our R&D rests not just on finding new treatments, but on getting better at how we find them. The key to that is combining human genetics, genomics and advanced technologies.
To fulfil our purpose to get ahead of disease together, we prioritise genetically validated targets to increase our probability of successfully delivering an approved vaccine or medicine.
Approximately 70% of our targets in research are genetically validated and published scientific research shows that genetically validated targets are at least twice as likely to become medicines.
We’re now able to harness advanced technologies to convert insights from human genetics and genomics to improve the probability of success for R&D.
Go Behind the Science to learn how advanced technologies like AI and ML power better predictions for patient impact
Using every tool we have to get ahead of disease
We are at the forefront of an exciting time in medical discovery. One fuelled by the genetic revolution of the last decade, combined with the expansion of patient-driven healthcare data and advanced technologies including artificial intelligence (AI) and machine learning (ML).
Advances in functional genomics, such as CRISPR gene editing, have already started to redefine what is possible in drug discovery. This is allowing researchers to unravel the mysteries of biology and help pinpoint novel drug targets with a higher probability of success.
These advances are driving a phenomenon we call the ‘digitisation of biology’, which allows scientists to explore human biology in a way never possible before. It holds much promise for treating diseases previously out of reach, and requires AI and ML.
“Digitisation, machine learning and AI are playing a major role in helping GSK speed up the vaccine research and manufacturing process.” – Tony Wood, Chief Scientific Officer-designate
Platform technologies
GSK has the broadest vaccine platform technology portfolio in the industry. This enables us to select the most promising technology approach (or combinations of different platform technologies) to develop new vaccines not previously thought possible.
Platform technologies such as adjuvants, bioconjugation, generalised modules for membrane antigen (GMMA) and adenovirus vectors can be used to make vaccines against a range of different pathogens and allow for a tailored approach to deliver success. This includes mRNA, a key focus area for our development as we see it as a critical platform technology and major opportunity for the future of vaccines.
learn more stuff
Using every tool we have to get ahead of disease
We are at the forefront of an exciting time in medical discovery. One fuelled by the genetic revolution of the last decade, combined with the expansion of patient-driven healthcare data and advanced technologies including artificial intelligence (AI) and machine learning (ML).
Advances in functional genomics, such as CRISPR gene editing, have already started to redefine what is possible in drug discovery. This is allowing researchers to unravel the mysteries of biology and help pinpoint novel drug targets with a higher probability of success.
These advances are driving a phenomenon we call the ‘digitisation of biology’, which allows scientists to explore human biology in a way never possible before. It holds much promise fo
Our new ambitious goals
“Digitisation, machine learning and AI are playing a major role in helping GSK speed up the vaccine research and manufacturing process.” – Tony Wood, Chief Scientific Officer-designate
